Lantheus Holdings Inc (NASDAQ:LNTH) was the recipient of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 766,671 shares, a drop of 54.0% from the October 31st total of 1,667,007 shares. Approximately 2.2% of the shares of the stock are sold short. Based on an average daily volume of 669,755 shares, the days-to-cover ratio is currently 1.1 days.

Several research analysts recently weighed in on LNTH shares. BidaskClub lowered Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 17th. ValuEngine lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Friday. Wells Fargo & Company upgraded Lantheus from a “market perform” rating to an “outperform” rating in a research report on Thursday, November 2nd. Credit Suisse Group increased their price objective on Lantheus from $19.00 to $23.00 and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Finally, Zacks Investment Research lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Wednesday, September 20th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Lantheus currently has a consensus rating of “Buy” and an average target price of $24.50.

In related news, SVP Timothy G. Healey sold 11,314 shares of the stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $21.51, for a total value of $243,364.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David F. Burgstahler sold 78,833 shares of the stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $16.95, for a total value of $1,336,219.35. Following the completion of the transaction, the director now owns 13,248 shares of the company’s stock, valued at $224,553.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 316,787 shares of company stock valued at $5,446,943. Insiders own 2.30% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System boosted its position in shares of Lantheus by 5.2% during the third quarter. California State Teachers Retirement System now owns 48,609 shares of the medical equipment provider’s stock worth $865,000 after buying an additional 2,409 shares during the period. Rhumbline Advisers boosted its position in shares of Lantheus by 5.0% during the third quarter. Rhumbline Advisers now owns 53,702 shares of the medical equipment provider’s stock worth $956,000 after buying an additional 2,560 shares during the period. New York State Teachers Retirement System boosted its position in shares of Lantheus by 13.4% during the third quarter. New York State Teachers Retirement System now owns 23,713 shares of the medical equipment provider’s stock worth $422,000 after buying an additional 2,800 shares during the period. LS Investment Advisors LLC boosted its position in shares of Lantheus by 47.1% during the third quarter. LS Investment Advisors LLC now owns 9,306 shares of the medical equipment provider’s stock worth $166,000 after buying an additional 2,981 shares during the period. Finally, Cubist Systematic Strategies LLC boosted its position in shares of Lantheus by 22.4% during the third quarter. Cubist Systematic Strategies LLC now owns 21,915 shares of the medical equipment provider’s stock worth $390,000 after buying an additional 4,015 shares during the period. Institutional investors and hedge funds own 92.05% of the company’s stock.

Lantheus (NASDAQ LNTH) opened at $21.85 on Friday. Lantheus has a 52-week low of $7.95 and a 52-week high of $24.10. The company has a market capitalization of $819.51 and a price-to-earnings ratio of 20.40. The company has a debt-to-equity ratio of -3.41, a quick ratio of 2.46 and a current ratio of 2.96.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported $0.24 EPS for the quarter, topping the consensus estimate of $0.20 by $0.04. Lantheus had a negative return on equity of 46.45% and a net margin of 9.59%. The business had revenue of $79.94 million during the quarter, compared to analyst estimates of $77.18 million. During the same period last year, the business posted $0.15 earnings per share. The company’s quarterly revenue was up 9.4% on a year-over-year basis. equities research analysts predict that Lantheus will post 1.05 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/12/02/short-interest-in-lantheus-holdings-inc-lnth-drops-by-54-0.html.

Lantheus Company Profile

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Receive News & Stock Ratings for Lantheus Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc and related stocks with our FREE daily email newsletter.